The european medicines agency approval of ingenol mebutate (Picato) for the cutaneous treatment of non-hyperkeratotic, non-hypertrophic actinic keratosis in adults: Summary of the scientific assessment of the committee for medicinal products for human use (chmp)

European Journal of Dermatology

Volumn 24, Issue 4, 2014, Pages 457-463

  Tzogani, Kyriaki ^a   Nagercoil, Nithyanandan ^b   Hemmings, Robert James ^b   Samir, Bekkai ^c   Gardette, Jean ^c   Demolis, Pierre ^c   Salmonson, Tomas ^d   Pignatti, Francesco ^a  

^a EUROPEAN MEDICINES AGENCY   (United Kingdom)

^b MEDICINES AND HEALTHCARE PRODUCTS REGULATORY AGENCY   (United Kingdom)

^c AFSSAPS   (France)

^d MEDICAL PRODUCTS AGENCY   (Sweden)

Author keywords

Actinic keratosis; EMA; Ingenol mebutate (Picato)

Indexed keywords

INGENOL MEBUTATE; 3-INGENYL ANGELATE; ANTINEOPLASTIC AGENT; DERMATOLOGICAL AGENT; DITERPENE; GEL;

ACTINIC KERATOSIS; ADULT; ARTICLE; DRUG APPROVAL; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; EROSION; ERYTHEMA; EUPHORBIA; HEALTH CARE QUALITY; HUMAN; INFLAMMATION; NONHUMAN; PHASE 3 CLINICAL TRIAL (TOPIC); PUSTULOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT DISEASE; RISK ASSESSMENT; SKIN CRUST; SKIN SCALE; SKIN SWELLING; SKIN ULCER; ADOLESCENT; ANIMAL; CHEMICALLY INDUCED; EUROPEAN UNION; FEMALE; GEL; INTRADERMAL DRUG ADMINISTRATION; KERATOSIS, ACTINIC; MALE;

ADMINISTRATION, CUTANEOUS; ADOLESCENT; ANIMALS; ANTINEOPLASTIC AGENTS; DERMATOLOGIC AGENTS; DITERPENES; DRUG APPROVAL; ERYTHEMA; EUROPEAN UNION; FEMALE; GELS; HUMANS; KERATOSIS, ACTINIC; MALE; RISK ASSESSMENT;

EID: 84922020036     PISSN: 11671122     EISSN: 19524013     Source Type: Journal    
DOI: 10.1684/ejd.2014.2368     Document Type: Article

References (30)

1. Holmes C, Foley P, Freeman M, Chong AH. Solar keratosis: epidemiology, pathogenesis, presentation and treatment. Australas J Dermatol 2007; 48: 67-74.
2. Einspahr JG, Stratton SP, Bowden GT, Alberts DS. Chemoprevention of human skin cancer. Crit Rev Oncol Hematol 2002; 41: 269-85.
3. Frost CA, Green AC, Williams GM. The prevalence and determinants of solar keratoses at a subtropical latitude (Queensland, Australia). Br J Dermatol 1998; 139: 1033-9.
4. Memon AA, Tomenson JA, Bothwell J, Friedmann PS. Prevalence of solar damage and actinic keratosis in a Merseyside population. Br J Dermatol 2000; 142: 1154-9.
5. Salasche SJ. Epidemiology of actinic keratoses and squamous cell carcinoma. J Am Acad Dermatol 2000; 42: 4-7.
6. Marks R, Foley P, Goodman G, Hage BH, Selwood TS. Spontaneous remission of solar keratoses: the case for conservative management. Br J Dermatol 1986; 115: 649-55.
7. Frost CA, Green AC. Epidemiology of solar keratoses. Br J Dermatol 1994; 131: 455-64.
8. Marks R, Rennie G, Selwood TS. Malignant transformation of solar keratoses to squamous cell carcinoma. Lancet 1988; 1: 795-7.
9. Stockfleth E, Ferrandiz C, Grob JJ, Leigh I, Pehamberger H, Kerl H. Development of a treatment algorithm for actinic keratoses: a European Consensus. Eur J Dermatol 2008; 18: 651-9.
10. Rivers JK, Arlette J, Shear N, Guenther L, Carey W, Poulin Y. Topical treatment of actinic keratoses with 3.0% diclofenac in 2.5% hyaluronan gel. Br J Dermatol 2002; 146: 94-100.
11. Rivers JK, McLean DI. An open study to assess the efficacy and safety of topical 3% diclofenac in a 2.5% hyaluronic acid gel for the treatment of actinic keratoses. Arch Dermatol 1997; 133: 1239-42.
12. Wolf JE Jr, Taylor JR, Tschen E, Kang S. Topical 3.0% diclofenac in 2.5% hyaluronan gel in the treatment of actinic keratoses. Int J Dermatol 2001; 40: 709-13.
13. Gebauer K, Brown P, Varigos G. Topical diclofenac in hyaluronan gel for the treatment of solar keratoses. Australas J Dermatol 2003; 44: 40-3.
14. Gupta AK. The management of actinic keratoses in the United States with topical fluorouracil: a pharmacoeconomic evaluation. Cutis 2002; 70: 30-6.
15. Lawrence N, Cox SE, Cockerell CJ, Freeman RG, Cruz PD Jr. A comparison of the efficacy and safety of Jessner’s solution and 35% trichloroacetic acid vs 5% fluorouracil in the treatment of widespread facial actinic keratoses. Arch Dermatol 1995; 131: 176-81.
16. Levy S, Furst K, Chern W. A comparison of the skin permeation of three topical 0.5% fluorouracil formulations with that of a 5% formulation. Clin Ther 2001; 23: 901-7.
17. Lebwohl M, Dinehart S, Whiting D, et al. Imiquimod 5% cream for the treatment of actinic keratosis: results from two phase III, randomized, double-blind, parallel group, vehicle-controlled trials. J Am Acad Dermatol 2004; 50: 714-21.
18. Morton CA, Brown SB, Collins S, et al. Guidelines for topical photodynamic therapy: report of a workshop of the British Photodermatology Group. Br J Dermatol 2002; 146: 552-67.
19. Szeimies RM, Karrer S, Radakovic-Fijan S, et al. Photodynamic therapy using topical methyl 5-aminolevulinate compared with cryotherapy for actinic keratosis: A prospective, randomized study. J Am Acad Dermatol 2002; 47: 258-62.
20. Szeimies RM, Radny P, Sebastian M, et al. Photodynamic therapy with BF-200 ALA for the treatment of actinic keratosis: results of a prospective, randomized, double-blind, placebo-controlled phase III study. Br J Dermatol 2010; 163: 386-94.
21. Ogbourne SM, Suhrbier A, Jones B, et al. Antitumor activity of 3-ingenyl angelate: plasma membrane and mitochondrial disruption and necrotic cell death. Cancer Res 2004; 64: 2833-9.
22. Challacombe JM, Suhrbier A, Parsons PG, et al. Neutrophils are a key component of the antitumor efficacy of topical chemotherapy with ingenol-3-angelate. J Immunol 2006; 177: 8123-32.
23. Rosen RH, Gupta AK, Tyring SK. Dual mechanism of action of ingenol mebutate gel for topical treatment of actinic keratoses: rapid lesion necrosis followed by lesion-specific immune response. J Am Acad Dermatol 2012; 66: 486-93.
24. Lebwohl M, Swanson N, Anderson LL, Melgaard A, Xu Z, Berman B. Ingenol mebutate gel for actinic keratosis. N Engl J Med 2012; 366: 1010-9.
25. Alomar A, Bichel J, McRae S. Vehicle-controlled, randomized, double-blind study to assess safety and efficacy of imiquimod 5% cream applied once daily 3 days per week in one or two courses of treatment of actinic keratoses on the head. Br J Dermatol 2007; 157: 133-41.
26. Jorizzo J, Dinehart S, Matheson R, et al. Vehicle-controlled, double-blind, randomized study of imiquimod 5% cream applied 3 days per week in one or two courses of treatment for actinic keratoses on the head. J Am Acad Dermatol 2007; 57: 265-8.
27. Swanson N, Abramovits W, Berman B, Kulp J, Rigel DS, Levy S. Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: results of two placebo-controlled studies of daily application to the face and balding scalp for two 2-week cycles. J Am Acad Dermatol 2010; 62: 582-90.
28. Nelson C, Rigel D, Smith S, Swanson N, Wolf J. Phase IV, open-label assessment of the treatment of actinic keratosis with 3.0% diclofenac sodium topical gel (Solaraze). J Drugs Dermatol 2004; 3: 401-7.
29. Krawtchenko N, Roewert-Huber J, Ulrich M, Mann I, Sterry W, Stockfleth E. A randomised study of topical 5% imiquimod vs. topical 5-fluorouracil vs. cryosurgery in immunocompetent patients with actinic keratoses: a comparison of clinical and histological outcomes including 1-year follow-up. Br J Dermatol 2007; 157 Suppl 2: 34-40.
30. Szeimies RM, Gerritsen MJ, Gupta G, et al. Imiquimod 5% cream for the treatment of actinic keratosis: results from a phase III, randomized, double-blind, vehicle-controlled, clinical trial with histology. J Am Acad Dermatol 2004; 51: 547-55.